New drug mosunetuzumab aims to control rare lymphoma without chemo
NCT ID NCT06569680
First seen Nov 03, 2025 · Last updated May 13, 2026 · Updated 21 times
Summary
This study tests a new drug called mosunetuzumab in people with a rare type of lymphoma (EMZL) who have not had any prior cancer treatment. The goal is to see if the drug can shrink or eliminate the cancer and how safe it is. About 35 adults with stage I to IV disease will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL MARGINAL ZONE LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.